E. Mendrinou

FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors

C. Sarri, Z. Mamuris, D. Sotiriadis, 2016, The Pharmacogenomics Journal.

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

G. Patrinos, A. Refaie, M. Mashaly, 2020, Frontiers in Pharmacology.

Novel genetic risk variants for pediatric celiac disease

B. Peters, R. Drmanac, G. Patrinos, 2016, Human Genomics.

Pharmacogenomics in Clinical Care and Drug Discovery

F. Innocenti, G. Patrinos, T. Katsila, 2017 .

Pharmacogenomics in Clinical Care: Implications for Public Health

G. Patrinos, Evangelia Eirini Tsermpini, Konstantina Chalikiopoulou, 2020 .

Novel genetic risk variants for pediatric celiac disease

B. Peters, R. Drmanac, G. Chrousos, 2016, Human Genomics.

Jacobs Journal of Pharmacology and Pharmacovigilance Cyp 3 A 5 * 3 is Not a Pharmacogenetic Marker for Cyclosporine Treatment Response in Psoriasis

Z. Mamuris, A. Roussaki-Schulze, Y. Vasilopoulos, 2015 .